Bifogade filer
Lytix Biopharma (Q3 Review) - Positive Clinical Readouts
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
2025-11-19 08:23:00
Redeye comments on Lytix' third quarter report 2025. After the quarter, positive results were presented in both main programmes. Lytix presented a strong interim readout in NeoLIPA, the study in neoadjuvant melanoma, while Verrica disclosed immune activation in biopsies of BCC.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/